MeVis Medical Solutions AG: Adjusting forecast for the current fiscal year
|
EQS-Ad-hoc: MeVis Medical Solutions AG / Key word(s): Change in Forecast Bremen, July 31, 2023 – MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading provider of medical imaging software, is adjusting its annual forecast for the current fiscal year based on the preliminary business figures for the first ten months. In light of a challenging macroeconomic environment with accelerating inflation and the ongoing war in Ukraine, MeVis Medical Solutions AG sees its revenue performance more cautious than before due to current project developments and subdued expectations in new projects. For fiscal year 2022/2023 (October 1, 2022 to September 30, 2023), revenues are now expected to decline to between € 17.0 million and € 17.5 million (previous forecast: stable revenues of € 18.0 million to € 18.5 million). EBIT (earnings before interest and taxes) is expected to be in a range of € 3.5 million to € 4.0 million in fiscal 2022/2023 in view of the changed assumptions (previous forecast: decline to € 4.5 million to € 5.0 million). In addition, earnings have been strongly impacted by the development of the US dollar/euro exchange rate since the beginning of the fiscal year.
Contact: Kirchhoff, Marcus / CEOEnd of Inside Information
31-Jul-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | MeVis Medical Solutions AG |
| Caroline-Herschel-Str. 1 | |
| 28359 Bremen | |
| Germany | |
| Phone: | +49 421 224 95 0 |
| Fax: | +49 421 224 95 999 |
| E-mail: | ir@mevis.de |
| Internet: | http://www.mevis.de |
| ISIN: | DE000A0LBFE4 |
| WKN: | A0LBFE |
| Listed: | Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1692327 |
| End of Announcement | EQS News Service |
|
|
1692327 31-Jul-2023 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.